What is RxTox?
RxTox operates as a CLIA-certified and state-licensed toxicology laboratory, serving as a critical partner for physicians, employers, and specialized treatment centers. The organization distinguishes itself through the deployment of sophisticated analytical methodologies, including enzyme immunoassay, gas chromatography/mass spectrometry, and liquid chromatography/mass spectrometry. By prioritizing high-precision drug detection and rapid result turnaround, RxTox has established a reputation for reliability and technical excellence. Its business model centers on providing customizable testing panels that address the evolving regulatory and clinical requirements of the modern healthcare landscape, ensuring that stakeholders receive actionable data with high integrity.
How much funding has RxTox raised?
RxTox has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in RxTox
PPP
Public-Private Partnership
What's next for RxTox?
The infusion of capital signals a transition into a more aggressive growth phase, likely focused on expanding the company's geographic footprint and technological capabilities. As the firm navigates the complexities of the late-stage funding environment, strategic priorities will likely include the integration of automated diagnostic workflows and the expansion of its proprietary testing panels. By leveraging this recent financing, RxTox aims to solidify its competitive advantage in the toxicology market, potentially exploring new partnerships with large-scale healthcare networks to drive volume and operational efficiency. The focus remains on maintaining rigorous quality control standards while scaling to meet the increasing demand for accurate, timely, and comprehensive diagnostic reporting.
See full RxTox company page
